Oncodesign Precision Medicine

Update in progress

ALOPM.PA (Paris)

Oncodesign Precision Medicine, a biopharmaceutical company, focuses on precision medicine. Its pipeline includes OPM-101, a RIPK2 inhibitor for inflammatory bowel disease and immuno-oncology; OPM-102 for cancer; and OPM-201, a LRRK2 inhibitor for Parkinson’s disease. The company also develops radiotheranostic molecules for diagnosing and treating advanced digestive cancers, and pancreatic and other cancers. Founded in 1995, it is based in Dijon, France.